Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study

Overview

Journal Acta Derm Venereol

Specialty Dermatology

Date 2020 Dec 7

PMID 33283248

Citations 2

Authors

Shany Sherman

Ory Zloczower

Yehonatan Noyman

Iris Amitay-Laish

Emmilia Hodak

Lev Pavlovsky

Affiliations

Soon will be listed here.

Abstract

The long-term effect of intra-anti-interleukin-17-class switch on drug survival is unclear. The aim of this study was to evaluate the efficacy and long-term survival of ixekizumab in bio-experienced psoriatic patients with and without previous exposure to anti-interleukin-17 treatment. Retrospective search of a tertiary medical centre database for 2017 to 2019 yielded 73 patients treated with ixekizumab: 50 previously exposed to secukinumab and 23 anti-interleukin-17-naïve. Median baseline Psoriasis Area Severity Index (PASI) was 23.0. Median number of received biologics was 4. Mean drug survival was 16.4 and 16.8 months in the anti-interleukin-17-exposed and naïve groups, respectively (p = 0.878). There was no between-group difference in proportion of patients achieving ≥ 75 PASI response. At study end, 25 anti-interleukin-17-exposed patients (50.0%) and 17 anti-interleukin-17-naïve patients (73.9%) were still on ixekizumab. The use of multiple previous biologic treatments was associated with substantially reduced ixekizumab survival. In conclusion, previous anti-interleukin-17-exposure was associated with an initially favourable response and did not further reduce ixekizumab survival.

Citing Articles

Comparative Analysis of Ixekizumab Effectiveness with and Without Induction Therapy in Moderate-to-Severe Psoriasis: A Real-World Study.

Ruiz-Villaverde R, Ezomo-Gervilla P, Molina-Espinosa J, Galan-Gutierrez M, Herrera-Acosta E, Suarez-Perez J J Clin Med. 2025; 14(3).

PMID: 39941503 PMC: 11818116. DOI: 10.3390/jcm14030833.

Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study.

Loft N, Egeberg A, Isufi D, Rasmussen M, Bryld L, Dam T Acta Derm Venereol. 2023; 103:adv12616.

PMID: 37987625 PMC: 10680979. DOI: 10.2340/actadv.v103.12616.

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population.

Berman J, Furer V, Berman M, Isakov O, Zisman D, Haddad A Biologics. 2021; 15:463-470.

PMID: 34819720 PMC: 8608411. DOI: 10.2147/BTT.S326792.

References

Egeberg A, Ottosen M, Gniadecki R, Broesby-Olsen S, Dam T, Bryld L . Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2017; 178(2):509-519. DOI: 10.1111/bjd.16102. View

Deza G, Notario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, Del Alcazar E . Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2018; 33(3):553-559. DOI: 10.1111/jdv.15288. View

Bissonnette R, Bolduc C, Poulin Y, Guenther L, Lynde C, Maari C . Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol. 2010; 63(2):228-34. DOI: 10.1016/j.jaad.2009.08.040. View

Egeberg A, Bryld L, Skov L . Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019; 81(1):173-178. DOI: 10.1016/j.jaad.2019.03.048. View

Georgakopoulos J, Phung M, Ighani A, Lam K, Yeung J . Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. J Eur Acad Dermatol Venereol. 2018; 33(1):e7-e8. DOI: 10.1111/jdv.15100. View

van den Reek J, van Vugt L, van Doorn M, van der Kraaij G, de Kort W, Lucker G . Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study. Acta Derm Venereol. 2018; 98(7):648-654. DOI: 10.2340/00015555-2900. View

Blauvelt A, Gooderham M, Iversen L, Ball S, Zhang L, Agada N . Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017; 77(5):855-862. DOI: 10.1016/j.jaad.2017.06.153. View

Kishimoto M, Komine M, Kamiya K, Sugai J, Mieno M, Ohtsuki M . Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2019; 47(1):33-40. DOI: 10.1111/1346-8138.15146. View

Loft N, Halling A, Egeberg A, Skov L . Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis. J Am Acad Dermatol. 2020; 84(1):130-138. DOI: 10.1016/j.jaad.2020.07.085. View

10.

Lunder T, Zorko M, Kolar N, Suhodolcan A, Marovt M, Leskovec N . Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int J Dermatol. 2019; 58(6):631-641. DOI: 10.1111/ijd.14429. View

11.

Esposito M, Prignano F, Rongioletti F, Hansel K, Bianchi L, Pescitelli L . Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice. J Dermatolog Treat. 2018; 30(5):441-445. DOI: 10.1080/09546634.2018.1529382. View

12.

Ortonne J, Chimenti S, Reich K, Gniadecki R, Sprogel P, Unnebrink K . Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol. 2011; 25(9):1012-20. DOI: 10.1111/j.1468-3083.2010.03944.x. View

13.

Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M . Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry. J Am Acad Dermatol. 2013; 70(2):257-62.e3. DOI: 10.1016/j.jaad.2013.10.019. View

14.

Langley R, Elewski B, Lebwohl M, Reich K, Griffiths C, Papp K . Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014; 371(4):326-38. DOI: 10.1056/NEJMoa1314258. View

15.

Kerdel F, Zaiac M . An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015; 28(6):390-403. PMC: 5042073. DOI: 10.1111/dth.12267. View

16.

Sherman S, Solomon Cohen E, Amitay-Laish I, Hodak E, Pavlovsky L . IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience. Acta Derm Venereol. 2019; 99(9):769-773. DOI: 10.2340/00015555-3200. View

17.

Bissonnette R, Luger T, Thaci D, Toth D, Messina I, You R . Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017; 177(4):1033-1042. DOI: 10.1111/bjd.15706. View

18.

Gordon K, Blauvelt A, Papp K, Langley R, Luger T, Ohtsuki M . Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016; 375(4):345-56. DOI: 10.1056/NEJMoa1512711. View

19.

Blauvelt A, Shi N, Burge R, Malatestinic W, Lin C, Lew C . Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. J Am Acad Dermatol. 2019; 82(4):927-935. DOI: 10.1016/j.jaad.2019.11.015. View

20.

Bokor-Billmann T, Schakel K . No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis. J Dermatolog Treat. 2018; 30(3):216-220. DOI: 10.1080/09546634.2018.1506081. View